Relación entre corticoterapia inhalatoria en pacientes con EPOC y severidad de SARS-COV2 en Hospital Víctor Lazarte Echegaray 2020- 2022
No Thumbnail Available
Date
2023
Journal Title
Journal ISSN
Volume Title
Publisher
Universidad Nacional de Trujillo
Abstract
Los corticoides inhalados (ICS) se utilizan para reducir la inflamación de las vías respiratorias, el edema, y secreciones de moco. Hay estudios realizados in vitro indica que la ciclesonida y la budesonida combinada con glicopirronio pueden suprimir la replicación del SARS-CoV-2 y se ha demostrado que el formoterol inhibe la producción de citocinas en pacientes que tuvieron COVID19.
La enfermedad pulmonar obstructiva crónica (EPOC) es un factor de riesgo de COVID-19. Los corticosteroides inhalados (ICS) se indican más frecuentemente para la prevención de las exacerbaciones agudas en personas con EPOC. El ICS es utilizado en pacientes que predomina las exacerbaciones y no hay mejoría con broncodilatadores de acción prolongada (LABA) o antimuscarínicos de acción prolongada (LAMA) y en sangre presenta eosinófilos >300 o si el paciente utiliza LABA+LAMA y tiene eosinófilos >= 100 podría ser tributario de adicionar los ICS. Con el uso de corticoide inhalado en pacientes con EPOC se vieron beneficios, disminuyendo los casos de complicaciones y de mortalidad. Por ello, se plantea la realización de esta investigación, dada la importancia de menos secuelas postcovid que dejaría esta enfermedad a lo largo del tiempo y la disminución de la mortalidad.
Inhaled corticosteroids (ICS) are used to reduce airway inflammation, edema, and mucus secretions. Studies conducted in vitro indicate that ciclesonide and budesonide combined with glycopyrronium can suppress the replication of SARS-CoV-2 and formoterol has been shown to inhibit cytokine production in patients who had COVID19. Chronic obstructive pulmonary disease (COPD) is a risk factor for COVID-19. Inhaled corticosteroids (ICS) are most frequently indicated for the prevention of acute exacerbations in people with COPD. ICS is used in patients whose exacerbations predominate and there is no improvement with long-acting bronchodilators (LABA) or long-acting antimuscarinics (LAMA) and the blood has eosinophils >300 or if the patient uses LABA+LAMA and has eosinophils >= 100 could be due to adding the ICS. Benefits were seen with the use of inhaled corticosteroid in patients with COPD, reducing cases of complications and mortality. For this reason, this research is proposed, given the importance of fewer post-covid sequelae that this disease would leave over time and the decrease in mortality.
Inhaled corticosteroids (ICS) are used to reduce airway inflammation, edema, and mucus secretions. Studies conducted in vitro indicate that ciclesonide and budesonide combined with glycopyrronium can suppress the replication of SARS-CoV-2 and formoterol has been shown to inhibit cytokine production in patients who had COVID19. Chronic obstructive pulmonary disease (COPD) is a risk factor for COVID-19. Inhaled corticosteroids (ICS) are most frequently indicated for the prevention of acute exacerbations in people with COPD. ICS is used in patients whose exacerbations predominate and there is no improvement with long-acting bronchodilators (LABA) or long-acting antimuscarinics (LAMA) and the blood has eosinophils >300 or if the patient uses LABA+LAMA and has eosinophils >= 100 could be due to adding the ICS. Benefits were seen with the use of inhaled corticosteroid in patients with COPD, reducing cases of complications and mortality. For this reason, this research is proposed, given the importance of fewer post-covid sequelae that this disease would leave over time and the decrease in mortality.
Description
Keywords
Enfermedad Pulmonar Obstructiva Crónica, COVID-19, Corticoides , Infección